<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03235557</url>
  </required_header>
  <id_info>
    <org_study_id>CYM Prostate CFB 1</org_study_id>
    <nct_id>NCT03235557</nct_id>
  </id_info>
  <brief_title>CyberKnife for Prostate Cancer Patients Aged 70 y or More</brief_title>
  <acronym>ProRobot</acronym>
  <official_title>Robotic Radiation Treatment of Prostate Cancer Patients Aged 70 y or More</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse, Luxembourg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse, Luxembourg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Robotic Stereotactic Radiation treatment of prostatic adenocarcinoma of the elderly.

      Inclusion criteria : T1-T3b, MRI pelvic nodes negative, M0, any Gleason Score, PSA (Prostate
      Specific Antigen) &lt;30ng/ml.

      Dose : 36.25 Gy in 5 fractions, in 10 days, considering CAPRA Scores≤5 AND 37.5 Gy in 5
      fractions, in 10 days, considering CAPRA Scores&gt;5.

      Primary objective : acute and late toxicity evaluation at 36 months. Secondary objectives :
      PSA and MRI response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Robotic Stereotactic Radiation treatment of prostatic adenocarcinoma of the elderly.

      Rationale : Half of the prostatic adenocarcinoma are diagnosed in the elderly but until now
      curative treatments were not proven to increase overall survival rates. Therefore, very
      short, comfortable and safe treatments have to be designed to increase the pelvic control of
      the disease. Moreover, the alpha/beta ratio of the disease ≤3Gray is in favour of using
      hypofractionation schemes.

      Primary objective : acute and late toxicity evaluation at 36 months. Secondary objectives :
      PSA and MRI response and quality of life evaluation.

      Inclusion criteria : T1-T3b, MRI pelvic nodes negative, M0, any Gleason Score, PSA&lt;30ng/ml.

      Dose : 36.25 Gray in 5 fractions, in 10 days, considering CAPRA Score≤5 AND 37.5 Gray in 5
      fractions, in 10 days, considering CAPRA Scores&gt;5.

      Doses to the Organs At Risk (OAR) : Rectum wall : V36.25&lt;2%, V27&lt;20%, V23&lt;30%, V20&lt;35%.
      Bladder wall : V36.25&lt;2%, V27&lt;20%, V20&lt;35%. Considering specifically the prescription of 37.5
      Gray, the rectum and bladder wall: V37.5&lt;2%. Anytime, hot spots of 105 % of the prescription
      dose must avoid the urethra.

      Evaluation criteria : CTCAEV4 (Common Toxicity Criteria for Adverse Events, version4), PSA,
      multiparametric MRI, IPSS (International Prostate Score Symptom) and IIEF5 (International
      Index of Erectile Function).

      Methodolgy : this is a three step prospective, observational study of 20 patients each step.
      Before moving to the next step, the severe acute or late toxicity at a median follow-up of 1
      year must remain below 5% each.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Acute and late toxicity (Using the CTCAEv4)</measure>
    <time_frame>During 36 months after treatment</time_frame>
    <description>Using the CTCAEv4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA evaluation</measure>
    <time_frame>at 4 and 6 months, than every 6 months for 3 years</time_frame>
    <description>PSA Dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital rectal exam</measure>
    <time_frame>at 6, 12, 24 and 36 months</time_frame>
    <description>Clinical examination (digital rectal exam)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birads score evaluation</measure>
    <time_frame>at 36 months</time_frame>
    <description>Multiparametric prostatic MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS evaluation</measure>
    <time_frame>at 12, 24 and 36 months</time_frame>
    <description>IPSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF5 evaluation</measure>
    <time_frame>at 12, 24 and 36 months</time_frame>
    <description>IIEF5 score</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly patients suffering prostatic adenocarcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T1-T3b,

          -  MRI pelvic nodes negative,

          -  M0,

          -  any Gleason Score,

          -  PSA&lt;30ng/ml,

          -  WHO (World Health Organisation) score&lt;2, IPSS≤15,

          -  maximal urinary flow rate ≥15ml/s,

          -  mean urinary flow rate ≥5ml/s,

          -  multiparametric prostatic and pelvis MRI

        Exclusion Criteria:

          -  Prostatic volume &gt; 100cc,

          -  TURP (transurethral prostatectomy) &lt;3 y,

          -  any recurrent prostatitis within the last 3 years,

          -  collagenose diseases,

          -  ulcero-haemorrhagic rectocolitis or

          -  crohn diseases
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Nickers, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Francois Baclesse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Untereiner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Francois Baclesse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peggy Binje, Data Manager</last_name>
    <phone>003522655661</phone>
    <email>peggy.binje@baclesse.lu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Esch Sur Alzette</city>
        <zip>4005</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Luxembourg</country>
  </location_countries>
  <results_reference>
    <citation>Nickers P, Hermesse J, Deneufbourg JM, Vanbelle S, Lartigau E. Which α/β ratio and half-time of repair are useful for predicting outcomes in prostate cancer? Radiother Oncol. 2010 Dec;97(3):462-6. doi: 10.1016/j.radonc.2010.06.006. Epub 2010 Aug 17.</citation>
    <PMID>20724012</PMID>
  </results_reference>
  <results_reference>
    <citation>Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, Cooley S, Timmerman R. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011 May 20;29(15):2020-6. doi: 10.1200/JCO.2010.31.4377. Epub 2011 Apr 4.</citation>
    <PMID>21464418</PMID>
  </results_reference>
  <results_reference>
    <citation>King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82. doi: 10.1016/j.ijrobp.2010.11.054. Epub 2011 Feb 6.</citation>
    <PMID>21300474</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>radiation</keyword>
  <keyword>stereotactic</keyword>
  <keyword>CyberKnife</keyword>
  <keyword>elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

